Bioequivalence testing for locally acting gastrointestinal products: what role for gamma scintigraphy?
Bioequivalence testing for locally acting gastrointestinal products is a challenging issue for both the pharmaceutical industry and the global regulatory authorities. It is widely accepted that for medicinal products not intended to be delivered into the systemic circulation, pharmacokinetic bioavailability cannot be used. However, it is becoming increasingly accepted that local availability may be assessed, where appropriate, by approaches that qualitatively reflect the presence of the active substance at the site of action. These methods must be specifically chosen for that combination of active substance and route of drug delivery. This paper argues for the use of gamma scintigraphy as a validated measure of local availability and bioequivalence for topically acting products administered to the gastrointestinal tract by the oral and rectal route.
Wilding
Ian
I
Pharmaceutical Profiles, Ltd., Ruddington, Nottingham, United Kingdom.
D000284:Administration, Oral; D000285:Administration, Rectal; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000493:pharmacokinetics*; D001682:Biological Availability; D002986:Clinical Trials as Topic; D004304:Dosage Forms; D005765:Gastrointestinal Agents / Q000493:pharmacokinetics*; D006801:Humans; D019804:Mesalamine / Q000493:pharmacokinetics; D011877:Radionuclide Imaging / Q000379:methods*; D013810:Therapeutic Equivalency; D013997:Time Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D004304:Dosage Forms; D005765:Gastrointestinal Agents; D019804:Mesalamine